Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.
Cowan-Jacob, S.W., Fendrich, G., Floersheimer, A., Furet, P., Liebetanz, J., Rummel, G., Rheinberger, P., Centeleghe, M., Fabbro, D., Manley, P.W.(2007) Acta Crystallogr D Biol Crystallogr 63: 80-93
- PubMed: 17164530 
- DOI: 10.1107/S0907444906047287
- Primary Citation of Related Structures:  
2HYY, 2HZ0, 2HZ4, 2HZI, 2HZN - PubMed Abstract: 
Chronic myelogenous leukaemia (CML) results from the Bcr-Abl oncoprotein, which has a constitutively activated Abl tyrosine kinase domain. Although most chronic phase CML patients treated with imatinib as first-line therapy maintain excellent durable responses, patients who have progressed to advanced-stage CML frequently fail to respond or lose their response to therapy owing to the emergence of drug-resistant mutants of the protein ...